189333-18-4

Basic information

• Product Name: 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, phenylMethyl ester
• Synonyms: 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, phenylMethyl ester;benzyl 9-oxo-3-azaspiro[5.5]undec-7-ene-3-carboxylate;9-oxo-3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid phenylmethyl ester
• CAS NO: 189333-18-4
• Molecular Formula: C₁₈H₂₁NO₃
• Molecular Weight: 299.36424
• Mol File: 189333-18-4.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, phenylMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, phenylMethyl ester(189333-18-4)
• EPA Substance Registry System: 3-Azaspiro[5.5]undec-7-ene-3-carboxylic acid, 9-oxo-, phenylMethyl ester(189333-18-4)

Safety Data

• Hazardous Substances Data: 189333-18-4(Hazardous Substances Data)

Upstream product

• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 78-94-4 methyl vinyl ketone 

Downstream Products

• 918651-00-0 9-(3,4-dichloro-phenyl)-9-hydroxy-3-aza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester 
• 1599479-01-2 rac-ethyl 2-(3-(2-chloro-5-(trifluoromethoxy)phenyl)-3-azaspiro[5.5 ]undec-9-yl)propanoate 
• 1599478-00-8 C₂₀H₂₃F₃N₂O₂S 
• 1599478-09-7 C₁₈H₂₃Cl₂NO₂ 
• 1599478-20-2 C₁₈H₂₂ClF₂NO₂ 
• 1599480-01-9 C₂₀H₂₃F₃N₂O₃ 
• 1599477-90-3 C₁₉H₂₃F₄NO₂ 
• 1599477-81-2 C₁₉H₂₃F₄NO₃ 
• 1599477-82-3 C₁₉H₂₆ClNO₃ 
• 1599477-77-6 (rac) 2-(3-(2-chloro-5-(trifluoromethoxy)phenyl)-3-azaspiro[5.5]undecan-9-yl)propanoic acid 

Relevant articles and documents

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Design, synthesis, and evaluation of novel and selective G-protein coupled receptor 120 (GPR120) spirocyclic agonists

Type 2 diabetes mellitus (T2DM) is an ever increasing worldwide epidemic, and the identification of safe and effective insulin sensitizers, absent of weight gain, has been a long-standing goal of diabetes research. G-protein coupled receptor 120 (GPR120) has recently emerged as a potential therapeutic target for treating T2DM. Natural occurring, and more recently, synthetic agonists have been associated with insulin sensitizing, anti-inflammatory, and fat metabolism effects. Herein we describe the design, synthesis, and evaluation of a novel spirocyclic GPR120 agonist series, which culminated in the discovery of potent and selective agonist 14. Furthermore, compound 14 was evaluated in vivo and demonstrated acute glucose lowering in an oral glucose tolerance test (oGTT), as well as improvements in homeostatic measurement assessment of insulin resistance (HOMA-IR; a surrogate marker for insulin sensitization) and an increase in glucose infusion rate (GIR) during a hyperinsulinemic euglycemic clamp in diet-induced obese (DIO) mice.

TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS

Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis